Categories AlphaGraphs, Earnings, Technology
Match Group stock soars as the market falls in love with Q2 results
Match Group Inc. (Nasdaq: MTCH) reported better-than-expected revenues and profit for the second quarter of 2019, aided mainly by a further strong increase in the memberships for its search app Tinder. The strong results sent the stock shooting 16% during post-market hours.
The Dallas, Texas-based company, which offers popular dating platforms such as Tinder, OkCupid and Match.com, posted a net profit of 43 cents per share for the June quarter, compared to $0.45 per share in the year-ago quarter. This was better than analysts’ estimate of 40 cents per share.
Revenue grew 18% annually to $498 million, driven by an 18% increase in average subscriber growth and a slight rise in revenue per user, which was partially offset by unfavorable foreign exchange effects. Analysts had expected revenue of $488.96 million.
At 5.2 million, average subscribers for Tinder were 1.5 million higher compared to last year.
The average revenue per user, excluding foreign exchange effects, moved up 2% to $0.58 during the three-month period.
READ: Meet Group reports Q2 earnings beat, but Q3 sales outlook disappoints
The stock has gained 74% since the beginning of this year and 94% in the trailing 12 months.
The dating company said it repurchased 0.8 million shares during the quarter ended June 30, 2019, for $56 million.
Most Popular
Agentforce in focus as Salesforce (CRM) gets ready for Q3 2025 earnings
After delivering mixed results in the first half, Salesforce, Inc. (NYSE: CRM) looks poised to report strong numbers when it publishes third-quarter results next week. The Customer relationship management platform
What to look for when Dollar Tree (DLTR) reports Q3 2024 earnings
Shares of Dollar Tree, Inc. (NASDAQ: DLTR) rose over 5% on Monday. The stock has dropped 27% over the past three months. The discount store chain is scheduled to report
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training